COSCIENS Biopharma Inc. Reports Q2 2026 Results
TORONTO, ONTARIO, Aug. 11, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCI.F) (“COSCIENS” or the “Company”) today reported its financial and operating results for the second quarter ended June 30, 2026. All amounts in this press release are in U.S. dollars. Q2 2026 and YTD Financial Highlights $5.3 million in cash and […]
COSCIENS Biopharma Inc. has released its Q2 2026 results, accompanied by a series of forward-looking statements and projections. The company's recent share reorganization and suspension of reporting obligations under U.S. securities laws have been highlighted as key factors contributing to its current position. Additionally, COSCIENS has provided insight into its future outlook and financial standing.
It is important to note that all forward-looking statements made by the company are in compliance with the safe harbor provisions of applicable securities legislation.
Written by urgent.news from Financial Post's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
